 SANTA MONICA, Calif., Dec. 10, 2020 GLOBE NEWSWIRE -- Opiant Pharmaceuticals, Inc. Opiant NASDAQ: OPNT, a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a 50 million convertible Note Purchase and Security Agreement Agreement with a syndicate of Pontifax Medison Finance Pontifax, a healthcare-dedicated venture and debt fund, and Kreos Capital, Europes leading growth debt firm. 